See more : Perennial International Limited (0725.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Nabriva Therapeutics plc (NBRV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Nabriva Therapeutics plc, a leading company in the Biotechnology industry within the Healthcare sector.
- Havix Corporation (3895.T) Income Statement Analysis – Financial Results
- LifeQuest World Corporation (LQWC) Income Statement Analysis – Financial Results
- Voyager Metals Inc. (VONE.V) Income Statement Analysis – Financial Results
- Telia Company AB (publ) (TLSNY) Income Statement Analysis – Financial Results
- Proximus PLC (PROX.BR) Income Statement Analysis – Financial Results
Nabriva Therapeutics plc (NBRV)
About Nabriva Therapeutics plc
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 35.67M | 27.22M | 2.86M | 7.75M | 6.50M | 0.00 | 0.00 | 84.00K | 0.00 | 0.00 |
| Cost of Revenue | 28.58M | 13.15M | 766.00K | 70.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 7.09M | 14.07M | 2.10M | 7.68M | 6.50M | 0.00 | 0.00 | 84.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 19.87% | 51.69% | 73.25% | 99.10% | 100.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 14.26M | 12.63M | 15.10M | 26.42M | 82.29M | 49.62M | 47.99M | 22.73M | 8.59M | 10.11M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 41.74M | 29.47M | 13.44M | 7.82M | 3.46M | 3.91M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 45.26M | 51.65M | 55.29M | 62.49M | 41.74M | 29.47M | 13.44M | 7.82M | 3.46M | 3.91M |
| Other Expenses | -1.27M | -1.68M | -2.16M | -1.73M | -272.00K | 492.00K | 55.00K | 2.86M | 77.82K | 34.30M |
| Operating Expenses | 58.26M | 62.60M | 68.22M | 87.17M | 120.88M | 73.77M | 55.05M | 26.84M | 9.89M | 6.74M |
| Cost & Expenses | 86.84M | 75.74M | 68.99M | 87.24M | 120.88M | 73.77M | 55.05M | 26.84M | 9.89M | 6.74M |
| Interest Income | 0.00 | 0.00 | 86.00K | 255.00K | 49.00K | 318.00K | 343.00K | 6.74M | 2.43K | 307.93K |
| Interest Expense | 698.00K | 0.00 | 1.74M | 3.64M | 133.00K | 43.00K | 75.00K | 14.59M | 6.98M | 5.55M |
| Depreciation & Amortization | -3.53M | 637.00K | 1.27M | 470.00K | 510.00K | 432.00K | 233.00K | 150.88K | 152.00K | 197.46K |
| EBITDA | -54.70M | -48.53M | -64.85M | -79.02M | -114.09M | -72.53M | -54.42M | -17.24M | -9.75M | 28.06M |
| EBITDA Ratio | -153.36% | -178.31% | -2,264.42% | -1,019.86% | -1,755.20% | 0.00% | 0.00% | -20,518.94% | 0.00% | 0.00% |
| Operating Income | -51.17M | -48.53M | -66.13M | -79.49M | -114.38M | -73.77M | -55.05M | -23.98M | -9.77M | 22.31M |
| Operating Income Ratio | -143.47% | -178.31% | -2,308.87% | -1,025.93% | -1,759.62% | 0.00% | 0.00% | -28,544.30% | 0.00% | 0.00% |
| Total Other Income/Expenses | -4.44M | -432.00K | -3.22M | -3.17M | -356.00K | 767.00K | -515.00K | 2.86M | -6.42M | -5.76M |
| Income Before Tax | -55.62M | -48.96M | -69.35M | -82.66M | -114.73M | -73.00M | -55.56M | -31.82M | -16.18M | 16.55M |
| Income Before Tax Ratio | -155.93% | -179.89% | -2,421.26% | -1,066.89% | -1,765.09% | 0.00% | 0.00% | -37,886.83% | 0.00% | 0.00% |
| Income Tax Expense | 1.57M | 490.00K | 139.00K | 101.00K | 49.00K | 1.36M | -672.00K | -438.41K | 87.55K | 1.07M |
| Net Income | -57.19M | -49.45M | -69.48M | -82.76M | -114.78M | -74.36M | -54.89M | -31.39M | -16.27M | 15.48M |
| Net Income Ratio | -160.33% | -181.69% | -2,426.12% | -1,068.20% | -1,765.85% | 0.00% | 0.00% | -37,364.91% | 0.00% | 0.00% |
| EPS | -21.32 | -28.52 | -135.23 | -278.86 | -564.91 | -623.15 | -638.90 | -741.38 | -149.52 | 142.25 |
| EPS Diluted | -21.32 | -28.52 | -135.23 | -278.86 | -564.91 | -623.15 | -638.90 | -741.38 | -149.52 | 130.92 |
| Weighted Avg Shares Out | 2.68M | 1.73M | 513.80K | 296.80K | 203.18K | 119.32K | 85.91K | 42.34K | 108.82K | 108.82K |
| Weighted Avg Shares Out (Dil) | 2.68M | 1.73M | 513.80K | 296.80K | 203.18K | 119.32K | 85.91K | 42.34K | 108.82K | 108.82K |
Nabriva Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Nabriva Therapeutics plc (NBRV) CEO Ted Schroeder on Q2 2022 Results - Earnings Call Transcript
Nabriva Therapeutics to Report Second Quarter 2022 Financial Results and Recent Corporate Highlights on August 3, 2022
Nabriva Therapeutics to Present at the H.C. Wainwright Global Investment Conference
Nabriva Therapeutics plc (NBRV) CEO Ted Schroeder on Q1 2022 Results - Earnings Call Transcript
Nabriva Therapeutics to Report First Quarter 2022 Financial Results and Recent Corporate Highlights on May 5, 2022
Nabriva Therapeutics plc (NBRV) CEO Ted Schroeder on Q4 2021 Results - Earnings Call Transcript
Nabriva Therapeutics to Report 2021 Financial Results and Recent Corporate Highlights on March 29, 2022
Nabriva Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference
Nabriva Therapeutics AG (NBRV) Loses 37.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Source: https://incomestatements.info
Category: Stock Reports